Abstract: A reagent composition for delivery nucleic acid therapeutics to cells is provided. The reagent includes ionizable lipid, structural lipid, and a stabilizing agent which improves the transfection efficiency of nucleic acids, and leaves transfected cells viable. The 5 transfection reagent is effective in plasmid and mRNA delivery, and in neurons and progenitor-like cells. It may be used for ex vivo cell therapy.
Type:
Grant
Filed:
April 15, 2019
Date of Patent:
June 20, 2023
Assignee:
Precision Nanosystems ULC
Inventors:
Anitha Thomas, Andrew William Brown, Rebecca Anne Grace De Souza, Tara L. Fernandez
Abstract: Described is an aqueous calcium gluconate solution formulated without calcium saccharate, which can be stored in a flexible plastic bag and can be terminally sterilized.
Abstract: An aqueous oral care fluoride treatment composition, a method of providing fluoride to a patients tooth surface, and a method of reducing the incidence of dental caries, wherein the composition includes: 0.5 wt-% to 4.8 wt-% of a water-soluble cationic N-containing polymer; a pharmaceutically acceptable buffer; 1.0 wt-% to 2.5 wt-% of sodium fluoride; and at least 60 wt-% water; wherein the weight percentages are based on the total weight of the aqueous composition.
Type:
Grant
Filed:
August 22, 2018
Date of Patent:
June 6, 2023
Assignee:
3M INNOVATIVE PROPERTIES COMPANY
Inventors:
Yizhong Wang, Tiffany T. Ton, Carola A. Carrera Vidal, Joel D. Oxman, Jennifer J. Post, Paul R. Klaiber
Abstract: A melt processed viral nanoparticle construct for delivery of virus or virus-like particles to a site of interest includes a degradable polymer matrix and a plurality of virus or virus-like particles encapsulated within the degradable polymer matrix. The nanoparticle construct upon administration to the site of interest providing a sustained release of the virus or virus-like particles and/or nanoparticles upon degradation of the polymer matrix.
Abstract: The present invention provides a new formulation which includes Elsholtzia ciliata Extract. Experiments have shown that ECE decreases the rate of depolarization of upstroke of myocardial action potential, slows the propagation of electrical excitation and distributes the ECG QRS range, i.e. treats the heart as a first-class anti-arrhythmic drug. Due to its herbal origin, the ECE can be well tolerated and widely used as a safe drug for eliminating cardiac arrhythmias.
Type:
Grant
Filed:
April 6, 2018
Date of Patent:
May 23, 2023
Assignee:
LIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS
Inventors:
Jurga Bernatoniene, Lauryna Pudziuvelyte, Jonas Jurevicius, Regina Macianskiene, Sandrita Simonyte
Abstract: Residence devices for long term delivery of therapeutic compounds and/or for sensing one or more relevant parameters in vivo are disclosed. In one embodiment, a residence device may include a plurality of links interconnected by a corresponding plurality of flexible hinges to permit the residence device to be deformed into a contracted configuration and subsequently permitted to return to an expanded configuration once positioned in a desired location, such as the stomach, of a subject. In some instances, at least a portion of the interconnected links may include a first link segment, a second link segment, and a coupling that selectively connects the first link segment to the second link segment. The coupling may be configured to weaken or decouple a connection between the first link segment and the second link segment when exposed to a temperature greater than a threshold temperature to selectively weaken and/or disassemble the residence device.
Type:
Grant
Filed:
November 15, 2019
Date of Patent:
May 16, 2023
Assignees:
Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
Inventors:
Robert S. Langer, Carlo Giovanni Traverso, Sahab I Babaee, Simo Pajovic, Jiuyun | Shi
Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.
Type:
Grant
Filed:
June 19, 2019
Date of Patent:
May 16, 2023
Assignee:
LTS LOHMANN THERAPIE-SYSTEME AG
Inventors:
Patrick Mohr, René Rietscher, René Eifler, Olga Bourquain
Abstract: Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.
Abstract: Diagnosing and treating viral infections. One example is a method of diagnosing absence of severe acute respiratory syndrome 2 (SARS-CoV-2), the method including: isolating a human in a covid-free environment for an isolation period; performing measurements of a core temperature during the isolation period; and if each of the measurements of the core temperature indicate a lack of fever, declaring the human free of SARS-CoV-2. Another example is a method including treating coronavirus in a human by: receiving a core temperature measurement; receiving a test result regarding the SARS-CoV-2 virus; responsive to the human having both fever and the presence of the SARS-CoV-2 virus, submerging the trunk and the legs of the human in water with a surfactant, and the human at least partially submerged for a treatment period of at least three hours; and controlling a temperature of the water during the treatment period.
Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
Type:
Grant
Filed:
June 2, 2021
Date of Patent:
April 25, 2023
Assignee:
THERASYN SENSORS, INC.
Inventors:
Jerome J. Schentag, Mary P. McCourt, Lawrence Mielnicki, Julie Hughes
Abstract: Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR—NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells.
Abstract: The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.
Abstract: The present disclosure relates to, inter alia, a formulation in a package. The formulation comprises one or more active agents and is co-mingled with a whipping agent prior to being filled under pressure into the package. The whipping agent is added in sufficient amounts to be dispersed in the formulation. The pressurized package is under sufficient pressure suitable to maintain the whipping agent dispersed in the formulation; and the pressurized package is under sufficient pressure to expel the formulation as a whipped formulation upon application of external force on the formulation in the package.
Type:
Grant
Filed:
May 11, 2017
Date of Patent:
April 11, 2023
Assignees:
FORMULATED SOLUTIONS, LLC, BEIERSDORF AG
Inventors:
Stephen Baldwin, Scott Carpenter, Heidi Graham, Nanhye Kim, Tom Meyer, David Reynolds, Jerry Vancleave, Eric Dann, Thomas Dann, Renee Nelson, Brian Dann
Abstract: The present disclosure relates to, inter alia, a formulation in a package, the formulation comprises one or more active agents and is co-mingled with a whipping agent prior to being filled under pressure into the package. The whipping agent is added in sufficient amounts to be dispersed in the formulation. The pressurized package is under sufficient pressure suitable to maintain the whipping agent dispersed in the formulation; and the pressurized package is under sufficient pressure to expel the formulation as a whipped formulation upon application of external force on the formulation in the package.
Type:
Grant
Filed:
May 11, 2017
Date of Patent:
March 28, 2023
Assignees:
FORMULATED SOLUTIONS, LLC, BEIERSDORF AG
Inventors:
Stephen Baldwin, Scott Carpenter, Heidi Graham, Nanhye Kim, Tom Meyer, David Reynolds, Jerry Vancleave, Eric Dann, Thomas Dann, Renee Nelson, Brian Dann
Abstract: The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.
Abstract: An object of the present invention is to provide an asenapine-containing patch having excellent sustained-release properties while enhancing skin permeability by using a silicone-based pressure-sensitive adhesive base. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, a silicone-based pressure-sensitive adhesive base and a release control agent, and the ratio of the maximum skin permeation rate of asenapine to the minimum skin permeation rate from the time when the maximum skin permeation rate is reached to 24 hours is less than 1.62.
Abstract: A gel composition is provided, including an alkaloid compound, or a cannabinoid compound, or both an alkaloid compound and a cannabinoid compound; glycerol; a viscosifying agent; a hydrogen-bond crosslinking gelling agent; and an ionic crosslinking gelling agent; and an acid.
Abstract: The present invention relates to antimicrobial formulations. More particularly, the invention relates to monovalent copper-containing and/or monovalent copper-generating products for healing wounds and burns, and particularly for chronic wounds, prevention of wound infections and infections in various implants as well as medical/surgical devices.
Abstract: An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.
Type:
Grant
Filed:
May 21, 2020
Date of Patent:
February 28, 2023
Assignee:
THE METHODIST HOSPITAL SYSTEM
Inventors:
Alessandro Grattoni, Edward Brian Butler, Ganesh Palapattu